Fernando Ruiz, MD
Interventional Cardiology · Lafayette, LANPI 1184662710
Payments from drug & device makers
Across 339 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$2K
- Abiomed$713
- Angiodynamics, Inc.$649
- Silk Road Medical, Inc.$637
- Novartis$457
- Johnson & Johnson$325
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,47697%
- Education$1983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 126 | $1,853 |
| Abiomed | 18 | $713 |
| Angiodynamics, Inc. | 11 | $649 |
| Silk Road Medical, Inc. | 8 | $637 |
| Novartis | 26 | $457 |
| Johnson & Johnson | 21 | $325 |
| E.r. Squibb & Sons, L.L.C. | 17 | $281 |
| Boston Scientific | 9 | $273 |
| Boehringer Ingelheim | 15 | $254 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $239 |
| Astellas Pharma US Inc | 3 | $207 |
| Medtronic(2 entities) | 5 | $190 |
| Inari Medical, Inc. | 1 | $189 |
| CSL Behring | 1 | $170 |
| Merck | 9 | $131 |
| Amgen | 8 | $130 |
| Philips North America LLC | 3 | $130 |
| Esperion Therapeutics, Inc. | 2 | $125 |
| Alnylam Pharmaceuticals Inc. | 4 | $109 |
| Novo Nordisk | 6 | $104 |
| Bard Peripheral Vascular, Inc. | 1 | $72 |
| Pfizer | 4 | $70 |
| Kowa Pharmaceuticals America, Inc. | 5 | $66 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Cardiovascular Systems Inc. | 3 | $34 |
| Scpharmaceuticals Inc. | 2 | $29 |
| Cvrx, Inc. | 1 | $28 |
| AstraZeneca | 2 | $27 |
| Penumbra, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Abbott | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Itamar Medical Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENROUTE Transcarotid Neuroprotection System$539
- ENROUTE Transcarotid Stent$539
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$377
- Impella$348
- FLOWTRIEVER CATHETER, S$189
- CT THROMBECTOMY SYSTEM KIT$189
- SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH THE SHOCKWAVE C2+ CORONARY$163
- COREVALVE EVOLUT R$139
- Auryon Laser System 100-120 Vac$120
- NEXLIZET$114
- NEXLETOL$114
How this compares
$7,674 in reported general payments places this provider in the 40th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 680 | $570,057 |
| EntrestoSacubitril/Valsartan | 249 | $239,132 |
| XareltoRivaroxaban | 183 | $192,100 |
| JardianceEmpagliflozin | 105 | $106,116 |
| OzempicSemaglutide | 78 | $81,580 |
| Repatha SureclickEvolocumab | 95 | $65,666 |
| NexlizetBempedoic Acid/Ezetimibe | 65 | $39,660 |
| FarxigaDapagliflozin Propanediol | 30 | $30,638 |
| MounjaroTirzepatide | 26 | $29,020 |
| BrilintaTicagrelor | 20 | $19,249 |
| Rosuvastatin Calcium | 1,202 | $18,354 |
| Ezetimibe | 787 | $16,584 |
| MultaqDronedarone Hcl | 15 | $12,346 |
| Metoprolol Succinate | 1,053 | $12,346 |
| Losartan Potassium | 967 | $11,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $70 | $570,057680 claims |
| NovartisEntresto | $457 | $239,132249 claims |
| Johnson & JohnsonXarelto | $325 | $192,100183 claims |
| Boehringer IngelheimJardiance | $254 | $106,116105 claims |
| Novo NordiskOzempic | $104 | $81,58078 claims |
| AstraZenecaFarxiga, Brilinta | $27 | $49,88750 claims |
| Lilly USA, LLCMounjaro, Trulicity | $18 | $40,08538 claims |
| Esperion Therapeutics, Inc.Nexlizet | $125 | $39,66065 claims |
| Sanofi-aventis U.S. LLCMultaq | $37 | $12,34615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Lafayette
- Ankur LodhaLafayette$945K
- Agostino IngraldiLafayette$315K
- Louis SalvaggioLafayette$214K
- Eric ThomasseeLafayette$149K
- Amit AminLafayette$82K
- Raghotham PatlolaLafayette$76K
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
- Mark NapoliMonroe$2.2M
- Stephen RameeNew Orleans$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.